{
    "2018-02-17": [
        [
            {
                "time": "2018-03-02",
                "original_text": "AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Positive",
                        "Phase 3",
                        "Psoriasis",
                        "Risankizumab"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-02",
                "original_text": "AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Late-Breaking",
                        "Phase 2b",
                        "Upadacitinib",
                        "Atopic Dermatitis"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-02",
                "original_text": "This Stock Gets a Gold Medal for Being the Best Blue Chip Biotech",
                "features": {
                    "keywords": [
                        "Stock",
                        "Gold Medal",
                        "Blue Chip",
                        "Biotech"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "The Hottest Investing Plays in the Booming Weed Industry for 2018",
                "features": {
                    "keywords": [
                        "Investing",
                        "Weed Industry",
                        "Booming"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "cannabis"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}